- Home
- NXC vs MGNX Comparison
NXC vs MGNX Comparison
Compare NXC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- MGNX
- Stock Information
- Founded
- NXC 1992
- MGNX 2000
- Country
- NXC United States
- MGNX United States
- Employees
- NXC N/A
- MGNX N/A
- Industry
- NXC Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NXC Finance
- MGNX Health Care
- Exchange
- NXC Nasdaq
- MGNX Nasdaq
- Market Cap
- NXC 81.7M
- MGNX 87.7M
- IPO Year
- NXC N/A
- MGNX 2013
- Fundamental
- Price
- NXC $12.79
- MGNX $1.33
- Analyst Decision
- NXC
- MGNX Hold
- Analyst Count
- NXC 0
- MGNX 9
- Target Price
- NXC N/A
- MGNX $5.33
- AVG Volume (30 Days)
- NXC 17.5K
- MGNX 2.0M
- Earning Date
- NXC 01-01-0001
- MGNX 08-05-2025
- Dividend Yield
- NXC 3.97%
- MGNX N/A
- EPS Growth
- NXC N/A
- MGNX N/A
- EPS
- NXC 0.19
- MGNX N/A
- Revenue
- NXC N/A
- MGNX $154,050,000.00
- Revenue This Year
- NXC N/A
- MGNX N/A
- Revenue Next Year
- NXC N/A
- MGNX N/A
- P/E Ratio
- NXC $70.47
- MGNX N/A
- Revenue Growth
- NXC N/A
- MGNX 255.31
- 52 Week Low
- NXC $11.86
- MGNX $0.99
- 52 Week High
- NXC $13.70
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- NXC 47.92
- MGNX 41.45
- Support Level
- NXC $12.72
- MGNX $1.33
- Resistance Level
- NXC $12.87
- MGNX $2.17
- Average True Range (ATR)
- NXC 0.10
- MGNX 0.17
- MACD
- NXC 0.00
- MGNX -0.02
- Stochastic Oscillator
- NXC 50.00
- MGNX 2.38
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.